Company search
Overview
Performance
Portfolio
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Data as at: 16/02/2026
In
Objective
To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.
AIC sector
Management group
Company website
Launch date
29/10/2019
December
Domicile
Guernsey
Fund manager
Naveen Yalamanchi, Roderick Wong, Woody Stileman, Oliver Kenyon
Dividend frequency
N/A
Wind-up provisions
The Company has an unlimited life.
| Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
|---|---|---|---|---|---|---|---|---|
| 688.65 | 773.51 | 2.11 | 2.37 | -10.97 | 0 | 0.00 | N/A | 1.75 (31/12/2024) |
Scroll
Dividends
Dividends declared in last 12 months
There have been no dividends in the last 12 months.
Performance (%)
| Return type | 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|---|
| RTW Biotech Opportunities | Share price total return | 57.5 | 61.1 | -8.3 | N/A |
| Biotechnology & Healthcare AIC sector | Share price total return | 15.3 | 2.2 | -18.8 | 103.3 |
Scroll
Share structure
Number of shares
326,373,649
19,593,791
Traded volumes (number of shares)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 365,341 | 9,114,274 | 161,300,168 | 365,863,196 |
| Average | N/A | 434,013 | 637,550 | 290,137 |
Scroll
Traded values (m)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 0.77 | 19.59 | 263.56 | 552.53 |
| Average | N/A | 0.93 | 1.04 | 0.44 |
Scroll
Trading details
| ISIN | Ticker | Traded currency | Stock exchange |
|---|---|---|---|
| GG00BKTRRM22 | RTW | USD | London Stock Exchange - MAIN Chi-x Europe Limited London Stock Exchange |
Scroll
Top holdings
Data as at : 30/06/2025
| Investment | % of total assets |
|---|---|
| Other Assets (Healthcare Sector) | 17.0 |
| Corxel Pharmaceuticals | 9.4 |
| Avidity Biosciences Inc Ordinary Shares | 8.7 |
| Akero Therapeutics Inc | 5.2 |
| Kailera Therapeutics | 5.0 |
| PTC Inc | 5.0 |
| UroGen Pharma Ltd | 4.6 |
| Zai Lab Ltd ADR Repr 1 Shs | 3.7 |
| uniQure NV | 3.4 |
| Taysha Gene Therapies Inc Ordinary Shares | 3.1 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
